Brad Loncar, CEO of Loncar Investments and creator of the indexes that power the Loncar Biotech ETFs, recently visited the Nasdaq MarketSite in New York and discussed trends he sees in the biotech industry. Watch the video above to hear his thoughts on where the cancer immunotherapy sector might be headed and why he believes China’s biopharma industry today is akin to the U.S. biotech industry in the 80’s and 90’s.
The Cancer Immunotherapy ETF (Nasdaq: CNCR) offers exposure to a basket of companies that develop therapies to treat cancer by harnessing the body’s own immune system. Immunotherapy is a transformational field within the biotechnology space that may have a foundational impact on cancer care. CNCR seeks to support this important work and its positive impact on society. It tracks the Loncar Cancer Immunotherapy Index. View CNCR holdings >
The China BioPharma ETF (Nasdaq: CHNA) offers exposure to a basket of companies powering China’s biopharmaceutical industry. With a long-term goal of steering its economy towards innovation, China aims to be a global leader in medicine. CHNA seeks to invest in this opportunity with the convenience of one security that trades in the United States. It tracks the Loncar China BioPharma Index. View CHNA holdings >
Opinions expressed are those of the author or Funds and are subject to change, are not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Fund holdings and allocations are subject to change at any time and should not be considered a recommendation to buy or sell any security. Amgen, Celgene, and Genentech’s parent company Roche are not a holding of the Funds or affiliated with the Funds.